Cargando…

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA

OBJECTIVES: Evaluating the cost-effectiveness of pembrolizumab plus standard chemotherapy in the first-line setting for patients with metastatic non-small cell lung cancer (NSCLC) from the US payer perspective. DESIGN: A Markov model was constructed to analyse the cost-effectiveness of pembrolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xiaohui, Wan, Xiaomin, Peng, Liubao, Peng, Ye, Ma, Fang, Liu, Qiao, Tan, Chongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924863/
https://www.ncbi.nlm.nih.gov/pubmed/31831534
http://dx.doi.org/10.1136/bmjopen-2019-031019
_version_ 1783481806944731136
author Zeng, Xiaohui
Wan, Xiaomin
Peng, Liubao
Peng, Ye
Ma, Fang
Liu, Qiao
Tan, Chongqing
author_facet Zeng, Xiaohui
Wan, Xiaomin
Peng, Liubao
Peng, Ye
Ma, Fang
Liu, Qiao
Tan, Chongqing
author_sort Zeng, Xiaohui
collection PubMed
description OBJECTIVES: Evaluating the cost-effectiveness of pembrolizumab plus standard chemotherapy in the first-line setting for patients with metastatic non-small cell lung cancer (NSCLC) from the US payer perspective. DESIGN: A Markov model was constructed to analyse the cost-effectiveness of pembrolizumab plus chemotherapy in the first-line treatment of metastatic NSCLC. Health outcomes were estimated in quality-adjusted life-years (QALYs). The cost information was from Medicare in 2018. One-way and probabilistic sensitivity analyses examined the impact of uncertainty and assumptions on the results. SETTING: The US payer perspective. PARTICIPANTS: A hypothetical US cohort of patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations. INTERVENTIONS: Pembrolizumab plus chemotherapy versus chemotherapy. PRIMARY OUTCOME MEASURES: Costs, QALYs, incremental cost-effectiveness ratio (ICER) of pembrolizumab plus chemotherapy expressed as cost per QALY gained compared with chemotherapy RESULTS: The base case analysis demonstrated that pembrolizumab plus chemotherapy provided an additional 0.78 QALYs at incremental cost of $151 409, resulting in an ICER of $194 372/QALY. ICER for pembrolizumab plus chemotherapy was >$149 680/QALY in all of our univariable and probabilistic sensitivity analyses. CONCLUSIONS: Pembrolizumab in addition to chemotherapy provides modest incremental benefit at high incremental cost per QALY for the treatment of previously untreated metastatic NSCLC.
format Online
Article
Text
id pubmed-6924863
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-69248632020-01-03 Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA Zeng, Xiaohui Wan, Xiaomin Peng, Liubao Peng, Ye Ma, Fang Liu, Qiao Tan, Chongqing BMJ Open Health Economics OBJECTIVES: Evaluating the cost-effectiveness of pembrolizumab plus standard chemotherapy in the first-line setting for patients with metastatic non-small cell lung cancer (NSCLC) from the US payer perspective. DESIGN: A Markov model was constructed to analyse the cost-effectiveness of pembrolizumab plus chemotherapy in the first-line treatment of metastatic NSCLC. Health outcomes were estimated in quality-adjusted life-years (QALYs). The cost information was from Medicare in 2018. One-way and probabilistic sensitivity analyses examined the impact of uncertainty and assumptions on the results. SETTING: The US payer perspective. PARTICIPANTS: A hypothetical US cohort of patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations. INTERVENTIONS: Pembrolizumab plus chemotherapy versus chemotherapy. PRIMARY OUTCOME MEASURES: Costs, QALYs, incremental cost-effectiveness ratio (ICER) of pembrolizumab plus chemotherapy expressed as cost per QALY gained compared with chemotherapy RESULTS: The base case analysis demonstrated that pembrolizumab plus chemotherapy provided an additional 0.78 QALYs at incremental cost of $151 409, resulting in an ICER of $194 372/QALY. ICER for pembrolizumab plus chemotherapy was >$149 680/QALY in all of our univariable and probabilistic sensitivity analyses. CONCLUSIONS: Pembrolizumab in addition to chemotherapy provides modest incremental benefit at high incremental cost per QALY for the treatment of previously untreated metastatic NSCLC. BMJ Publishing Group 2019-12-11 /pmc/articles/PMC6924863/ /pubmed/31831534 http://dx.doi.org/10.1136/bmjopen-2019-031019 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Health Economics
Zeng, Xiaohui
Wan, Xiaomin
Peng, Liubao
Peng, Ye
Ma, Fang
Liu, Qiao
Tan, Chongqing
Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
title Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
title_full Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
title_fullStr Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
title_full_unstemmed Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
title_short Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
title_sort cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the usa
topic Health Economics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924863/
https://www.ncbi.nlm.nih.gov/pubmed/31831534
http://dx.doi.org/10.1136/bmjopen-2019-031019
work_keys_str_mv AT zengxiaohui costeffectivenessanalysisofpembrolizumabpluschemotherapyforpreviouslyuntreatedmetastaticnonsmallcelllungcancerintheusa
AT wanxiaomin costeffectivenessanalysisofpembrolizumabpluschemotherapyforpreviouslyuntreatedmetastaticnonsmallcelllungcancerintheusa
AT pengliubao costeffectivenessanalysisofpembrolizumabpluschemotherapyforpreviouslyuntreatedmetastaticnonsmallcelllungcancerintheusa
AT pengye costeffectivenessanalysisofpembrolizumabpluschemotherapyforpreviouslyuntreatedmetastaticnonsmallcelllungcancerintheusa
AT mafang costeffectivenessanalysisofpembrolizumabpluschemotherapyforpreviouslyuntreatedmetastaticnonsmallcelllungcancerintheusa
AT liuqiao costeffectivenessanalysisofpembrolizumabpluschemotherapyforpreviouslyuntreatedmetastaticnonsmallcelllungcancerintheusa
AT tanchongqing costeffectivenessanalysisofpembrolizumabpluschemotherapyforpreviouslyuntreatedmetastaticnonsmallcelllungcancerintheusa